Mary Kay supports female empowerment, entrepreneurship, equality

KUALA LUMPUR, Nov 20 -- Mary Kay Inc continues to advocate for global female empowerment, entrepreneurship and equality by addressing the issues during top women’s conferences worldwide.

The company actively participated in two important international conferences - International Women’s Forum World Leadership Conference in Toronto, Canada and the Reykjavik Global Forum – Women Leaders in Reykjavik, Iceland.

During the Canada conference, leading female architects, advocates, catalysts and pioneers of change from over 50 countries discussed challenges that faced women today, and how best to approach them.

Mary Kay Canada, Director PR, Digital & Product Marketing, Michelle Haurilak was on-hand to speak and introduce a session on Becoming a Dangerous Woman, an interview with television powerhouse and editorial director of TEDWomen, Pat Mitchell.

Meanwhile at the Iceland conference, Mary Kay Chief Legal Officer and Corporate Secretary, Julia Simon joined other female leaders to discuss and share ideas and solutions on how to further advance society, increase gender equality as well as promote and positively develop women in leadership positions.

Simon also attended a Leadership Luncheon hosted by Concordia, tackling themes such as investing in female entrepreneurs, women’s global health, political leadership and education.

Recently, in collaboration with six United Nations agencies, Mary Kay announced the Women’s Entrepreneurship Accelerator empowered by Mary Kay, a multi-year partner initiative designed to inspire, educate and empower women entrepreneurs globally.

-- BERNAMA

PUTRA BUSINESS SCHOOL UNVEILS DISTINGUISHED PERSONALITIES (GRADUANDS) AT 43RD UPM CONVOCATION CEREMONY 2019

SERDANG,  Nov 19 (Bernama) -– 138 Putra Business School (PBS) graduates will be conferred with their degrees at the 43rd UPM Convocation Ceremony upon successful completion of their MBA, MSc and Ph.D. programmes on 19th November 2019.

“My PhD journey was not an easy path. But since this kind of opportunity is rare, so I had to finish where I started. Quitting was never my option. Positive mindset, persistence, family support and DOA (prayers) were my critical success factors in getting through my doctoral programme (in finance), along-side winning the coveted gold medal in Asian Cycling Championships” said Dr Norhasmat Abdul Aziz.

“PBS's line up of experience, scholarly and industry-driven lecturers, have been the pulling factors to me personally, notwithstanding my other industrious colleagues, towards investing in our unique intellectual-industrial capital. The aim was to strike a balance between striving for an academic excellence and internalising the real time work culture, within the student population, comprising peoples of wide-ranging nationalities.  PBS, thus, has provided me with rich intercultural learning experience, an imperative in the current corporate cultural processes.  Therefore, such a pleasurable and unforgettable learning journey offered to me was made possible by the learned and competent team of lecturers and the administration staff”, said Dr Siti Zubaidah Mohd Ariffin, former cabin crew who is conferred with Ph.D. (Management).

Dr Sitti Rahma Abd Hafid, a Ph.D holder in Medical and Health Science, will be conferred an MBA (General Management). “I feel honoured and privileged to be part of Putra Business School.  I truly feel that the school has laid a strong Business and Management foundation considering my different background i.e. Medical and Health Sciences.   The decision to pursue an MBA actually was to dig more knowledge on business and management.  The journey, in fact, was most challenging.  However, the return is most satisfying, knowing the fact that PBS is one of the most established and first AACSB Accredited Business School in Malaysia”.

In meanwhile, two graduands were conferred the most prestigious awards for their academic excellence i.e. President’s Award for Joanna Jayaprakash and Human Governance Award for Hafizah Abdul Aziz.

ABOUT PUTRA BUSINESS SCHOOL
Putra Business School (PBS) was formerly known as the Graduate School of Management (GSM), Universiti Putra Malaysia (UPM). It is a leading business school in Malaysia and the first post-graduate business school accredited by AACSB - The Association to Advance Collegiate Schools of Business. Only less than 5% of business schools, worldwide, have the honour of such accreditation. PBS is also accredited by ABEST21 (The Alliance on Business Education and Scholarship for Tomorrow, a 21st Century Organization). In addition, all programmes offered by PBS are accredited by the Malaysian Qualifications Agency (MQA), as approved by the Ministry of Education.

The academic programmes offered by PBS include MBA (General Management) and MBA (Corporate Governance), are conducted in collaboration with Malaysian Institute of Chartered Secretaries and Administrators (MAICSA). While MBA (Marketing) and MBA ((Human Potential Management) are conducted in collaboration with the Institute of Marketing Malaysia and Malaysian Institute of Human Resource Management, respectively. Other programmes offered are:  MBA (Finance), MBA (International Business), MBA (Accounting), specialised Master of Science (MSc) and specialised Doctor of Philosophy (PhD). For more information, please visit our website at http://www.putrabusinessschool.edu.my.

Source: Putra Business School (PBS)

VISTA EQUITY PARTNERS ANNOUNCES ASIA EXPANSION

Vista Consulting Group’s Singapore Office Will Further Support Portfolio Company Operations in the Region

SINGAPORE & AUSTIN, Texas Nov 18 (Bernama-BUSINESS WIRE) -- Vista Equity Partners today announced the opening of Vista Consulting Group’s (“VCG”, and together with Vista Equity Partners, “Vista”) Singapore office. VCG is the affiliated consulting arm of Vista, the leading investment firm focused on enterprise software, data, and technology-enabled businesses. The new office will serve as the Asia headquarters for VCG, expanding Vista’s presence and providing additional operational support for Vista companies in the region and their almost 14,000 employees.

The Singapore office, located in the Centennial Tower, is indicative of the firm’s continued strong commitment to Asia. Currently, more than 20 Vista portfolio companies have offices in the region, with 13 in Singapore. As part of the announcement, Vista portfolio company Apptio, a provider of software that fuels digital transformation, named Singapore as its Asia headquarters as it focuses on driving sales and other opportunities throughout the region. Another Vista portfolio company, RDC, announced earlier this year that it also was naming Singapore its Asia headquarters.

“We are seeing immense growth of the business-to-business market in Asia, underpinned by an acceleration of investment in technology infrastructure and enterprise software,” said Robert F. Smith, Founder, Chairman, and CEO of Vista. “This transformation continues to create a significant commercial opportunity across our portfolio. An on-the-ground presence in Singapore builds upon our extensive work in India and other parts of the region and will improve our ability to support the growth of our companies by further helping our network engage with customers, partners, entrepreneurs and technology talent to best position them and Vista for continued success.”

Vista was one of the first investment firms to develop its own dedicated consulting organization. Vista draws on nearly two decades of expertise and best practices investing in and operating enterprise software companies and is committed to partnering with entrepreneurs, founders and executives to grow their companies through capital as well as operational support.

Vista’s Singapore office opening ceremony was held on Friday and attended by representatives from the Monetary Authority of Singapore and other strategic partners, executives from Vista portfolio companies, and government and business leaders from across the region.

About Vista Equity Partners and Vista Consulting Group

Vista Equity Partners is a U.S.-headquartered investment firm with offices in Austin, Chicago, New York City, Oakland, and San Francisco and more than $52 billion in cumulative capital commitments. Vista exclusively invests in enterprise software, data, and technology-enabled organizations across private equity, credit, public equity, and permanent capital strategies. As a value-added investor with a long-term perspective, Vista contributes professional expertise and multi-level support towards companies to realize their full potential. Vista’s dedicated consulting arm, Vista Consulting Group, supports Vista companies globally. Vista’s investment approach is anchored by a sizable long-term capital base, experience in structuring technology-oriented transactions, and proven management techniques that yield flexibility and opportunity. For more information, please visit www.vistaequitypartners.com.

View source version on:
 https://www.businesswire.com/news/home/52129095/en

Contact

Media Contacts
Alan H. Fleischmann
vista@laurelstrategies.com
+1-202-776-7776

Source : Vista Equity Partners

--BERNAMA

PHENOMICS HEALTH INC. ACQUIRES PATENTED PHARMACOMETABOLOMIC TECHNOLOGY

First Integrated Pharmacogenomics and Metabolomics Platform Offers Potential to Improve Patient Outcomes, Lower Costs in Medication Therapy


ANN ARBOR, Mich., Nov 22 (Bernama-BUSINESS WIRE) -- Phenomics Health Inc., a bioinformatics platform-based precision medicine company, today announced it has acquired the patented pharmacometabolomic technology portfolio of Precera Bioscience, based in Franklin, Tenn.

Phenomics Health plans to integrate the new technology with its own patented, advanced pharmacogenomics platform to offer healthcare providers a more complete view of patients’ potential and actual response to medications than is currently available.

To be marketed under the PrecīsMed brand and licensed to clinical laboratories and healthcare systems, this patented pharmacometabolomic technology enables detection, quantitative measurement, and comprehensive assessment of more than 200 medications in a patient’s bloodstream.

Combined with Phenomics Health’s technology, the resulting information from PrecīsMed will help clinicians personalize drug therapy by determining what medications and dose a patient is actually taking (whether prescribed or not), drug-drug interactions, and how genetics may impact the body’s ability to process those medications.

“This is the first time that both advanced pharmacogenomics and pharmacometabolomics platforms have come together under one roof,” said Dr. James S. Burns, co-founder, Chairman and President, Phenomics Health. “PrecīsMed could help improve patient treatment outcomes, avoid adverse drug reactions, and reduce patient treatment costs – the real definition of precision medicine.”

Current Medication Therapy Remains Ineffective

Studies have found that 33% of medications taken by patients are not in their medical record, and approximately 50% of prescribed medications are not taken at all. In addition, about 55% of medications are taken at levels outside of their prescribed range while another 50% experience significant drug interaction alerts arising from unknown medications.^1,2,3,4

“Poor adherence to medication leads to increased morbidity and death and is estimated to incur costs of approximately $100 billion per year⁵,” according to a report published in the Mayo Clinic Proceedings.

Patients who suffer from comorbid disorders often require treatments with multiple medications, which can result in missed, wrong, or multiple dosages. Additionally, genetics can play a role in determining whether a medication is as effective as it could or should be, as well as disease state, drug-drug interactions, and socio-cultural or environmental conditions.

Clinical studies published in 2018 have demonstrated that PrecīsMed can accurately assess prescribing trends, medication adherence and electronic health record (EHR) coverage, as well as define medication concentrations in patients with comorbid disorders.⁶

Phenomics Health also plans to use the information gathered from de-identified patient population data to inform its machine learning and AI-based bioinformatics platform, which can be mined for present and future research.

How it Works

A patient’s blood sample is obtained using a simple finger stick. The sample would then be analyzed using Phenomics Health’s patented methods, algorithms, and data analytics to identify and measure medications in a patient’s bloodstream.

The PrecīsMed technology is applicable for identifying medications used in treating multiple patient disorders, including depression, anxiety, chronic pain, post-operative pain, opioid usage, cardiovascular and metabolic disease, diabetes, and hypertension.

“Our newly enhanced platform integrates Phenomics Health’s disease-drug response network discoveries and patient pharmacometabolomic profiles to enhance the precision and predictability of medication selection,” said Dr. Brian D. Athey, co-founder, Chief Science and Technology Officer, Phenomics Health. “The information gathered through its use could change the direction of how clinicians prescribe and manage medications, greatly improving a patient’s response.”

About Phenomics Health Inc.

Phenomics Health Inc. (PHI) is a bioinformatics platform-based precision medicine company using artificial intelligence and machine learning to translate advanced genetic, epigenetic, multi-omics, and health Big Data into novel pharmacological clinical treatment decision support products and services.

PHI’s proprietary Phenome Analytics Platform is designed to help clinicians and health systems select appropriate medications, drug combinations and doses that improve individual patient and population health outcomes while reducing adverse drug reactions. Discoveries from the University of Michigan Medical School, leading to exclusive licensed proprietary informatics technology, form the basis for Phenomics Health’s products and services.

Products and services developed by PHI will focus on variants in the non-coding domain of the human genome consisting of spatial, temporal, and mechanical regulatory mechanisms of gene regulation. A transformative understanding of regulatory genomics, the transcriptional hierarchy, and the structural dynamics of the nucleus has provided the ability to resolve previously unrecognized mechanisms of action across multiple therapeutic areas. Phenomics Health also provides contract and collaborative research services to test mechanisms and pathways for new or repurposed drugs.

For more information about Phenomics Health, please visit www.phenomicshealth.com.

Registered trademarks are the property of Phenomics Health Inc.

References:
1. BusinessWire. (2018, April 16). MediMergent and FDA Launch New Stakeholder Initiative against Medication Non-Adherence/Persistence Crisis [Press release]. Retrieved from https://bwnews.pr/2p6adS4
2. Data on File
3. Sabaté E, editor., ed. Adherence to Long-Term Therapies: Evidence for Action. Geneva, Switzerland: World Health Organization; 2003.
4. Lee JK, Grace KA, Taylor AJ. Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial. JAMA. 2006;296(21):2563-2571
5. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487-497 [PubMed] [Google Scholar]
6. JAMA Network Open. 2018;1(7):e184196. doi:10.1001/jamanetworkopen.2018.4196

View source version on businesswire.com: 
https://www.businesswire.com/news/home/20191122005027/en/

Contact

James S. Burns, Chairman & President
Phenomics Health Inc.
jburns@phenomicshealth.com
734.961.7211

Rick Miller
Rick Miller Communications
rick@rickmillercommunications.com
513.608.8463

Source : Phenomics Health Inc.

PIALIVING: FINALLY JAPANESE SOUNDPROOF PRODUCTS ARE COMING IN SINGAPORE!

FUKUOKA, Japan, Nov 22 (Bernama-BUSINESS WIRE) -- Pialiving Co., Ltd. is opening a Japanese soundproof POP-UP store at Tokyu Hands Suntec City until November 24th, 2019.

Above all, many people are interested in soundproof curtains that can reduce the construction noise from the outside and the noise from the neighbor.

The products are sold exclusively in Tokyu Hands Suntec City.

The sale will end when all the stock is sold out.

[Period] 28th October 2019 (Mon) - 24th November 2019 (Sun)

[Location] Tokyu Hands Suntec City

[Company URL] https://www.pialiving.com

View source version on businesswire.com:
https://www.businesswire.com/news/home/20191121006079/en/

Contact

Contact: https://www.pialiving.com/
Pialiving Co., Ltd.
Haruka Muromizu
TEL: +65-92-432-7011
Mail: pia@pialiving.co.jp
 
Source : Pialiving Co., Ltd.